Forum: Crucell » J&J neemt 18$ belang in Crucell voor 301mln » Pagina: 29

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Vanaf 13,95 per maand leest u dagelijks onze professionele aandelenanalyses en kooptips.

Krijg toegang tot vele voordelen

Onbeperkt toegang tot onze Premium-content
Ons magazine IEX Expert (digitaal of papier)
Toegang tot onze 3 modelportefeuilles

Profiteer van de IEX producten

3 Modelportefeuilles
Dividendkalender
Aandelenselector

flosz 17 december 2009 12:44

UPDATE 1-J&J to pay $785 million for sinus-surgery company
Deal gives J&J new sinus-surgery approach
* Cash deal includes other ear, nose, throat technology
By Ransdell Pierson
NEW YORK, Dec 16 (Reuters) - Johnson & Johnson , in the latest of a string of significant deals this year, on Wednesday said it would pay $785 million in cash to acquire privately held Acclarent Inc and its sinus-surgery technology.
J&J, which sells an array of medical devices as well as drugs and consumer products, said the deal will be net of estimated cash on hand at the time of its expected closing in the first quarter of 2010.
"Acclarent's focus is on achieving the goals of sinus surgery with novel, endoscopic, minimally-invasive devices," J&J said in a release.
It said Acclarent's so-called balloon sinuplasty technology and other innovative products offer an alternative to conventional surgical approaches, including treatment of sleep apnea.
The deal will depress J&J's 2010 earnings by three to four cents per share, the diversified healthcare company said.
J&J last month announced it will cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges.
Earlier this year, the New Brunswick, New Jersey based company said it would eliminate 900 positions from its Ortho-McNeil-Janssen Pharmaceutical unit.
By bolstering its finances, cost savings have helped enable J&J to acquire stakes this year in Irish drugmaker Elan Corp and Dutch vaccine company Crucell . In May, J&J agreed to buy cancer drug developer Cougar Biotechnology for $970 million in cash.
J&J needs revenue from promising new products to offset plunging sales of its big medicines now facing generic competition, including schizophrenia treatment Risperdal and anti-convulsant Topamax. (Reporting by Ransdell Pierson; editing by Gunna Dickson)
www.forexpros.com/news/general-news/u...

www.jnj.com/connect/news/all/20091216...

Direct naar Forum

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

AEX	872,50	-0,17%
EUR/USD	1,0718	+0,19%
FTSE 100	8.083,90	+0,54%
Germany40^	18.000,70	-0,49%
Gold spot	2.322,61	+0,28%
NY-Nasdaq Composite	15.712,75	+0,10%

UNILEV...	+1,98 +4,40% 1.98 4.4039
Fugro	+0,50 +2,18% 0.5 2.1815
Flow T...	+0,38 +1,95% 0.38 1.9477
NX FIL...	+0,06 +1,85% 0.06 1.8519
Avantium	+0,02 +1,00% 0.025 1.004

ADYEN NV	-202,60 -14,28% -202.6 -14.2837
VIVORY...	-0,07 -7,82% -0.07 -7.8212
BESI	-7,35 -5,29% -7.35 -5.2878
WDP	-1,26 -4,93% -1.26 -4.9296
IMCD	-3,20 -2,11% -3.2 -2.1122

Beurscodes, betekenis en hulp bij zoeken

Europa

Noord-Amerika

Kunt u een instrument niet vinden?

Waar vind ik die ISIN code?

Inloggen

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Krijg toegang tot vele voordelen

Profiteer van de IEX producten

Nederland

Europa

Amerika

Crucell« Terug naar discussie overzicht

J&J neemt 18$ belang in Crucell voor 301mln

aossa

Aanbevelingen

Aantal posts: 17.586

aossa

Aanbevelingen

Aantal posts: 17.586

flosz

Aanbevelingen

Aantal posts: 7.005

Meedoen aan de discussie?

Direct naar Forum

Indices

Stijgers

Dalers

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Bitvavo

Hét Warren Buffett-pakket al aangevraagd?

Nederlandse MKB Participatiemaatschappij

Pearl Capital: beleggen met zekerheid

Meld u aan voor de dagelijkse Beursupdate

Verzoek